Kerala Ayurveda Ltd (KERALAYUR) — shareholding pattern, promoter holding, financials and share price
About Kerala Ayurveda Ltd (KERALAYUR)
Kerala Ayurveda Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as KERALAYUR and on the BSE under scrip code 530163. Its ISIN is INE817B01025.
Incorporated in 1945, Kerala Ayurveda Ltd is engaged In Ayurvedlc services and products [1]
Kerala Ayurveda Ltd, founded in July 1992, specializes in manufacturing Ayurvedic products and offers a wide range of services including clinics, hospitals, and wellness resorts.
The company is expanding its capacity with a modern facility at Athani, enhancing its ability to produce both patent and traditional Ayurvedic medicines.
Listed peers in Pharmaceuticals: Ambalal Sarabhai Enterprises Ltd, Nectar Lifescience Ltd, Coral Laboratories Ltd, Syschem (India) Ltd, Brooks Laboratories Ltd, Gujarat Inject (Kerala) Ltd.
Valuation & Returns
10 Jul 2026At ₹165.75 a share on 10 Jul 2026, Kerala Ayurveda Ltd (KERALAYUR) was valued at a price-to-book of 22.69x on a book value of ₹7.31 per share as of Mar 2025. Solomo computes return on equity of -172.01% and return on capital employed of -11.25% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- Industry P/E
- 36.41x
- P/B
- 22.69x
- EPS (TTM)
- ₹-12.57
- Book value / share
- ₹7.31
- ROE
- -172.01%
- ROCE
- -11.25%
- ROA
- -12.68%
- Debt / equity
- 7.44x
- Dividend yield
- 0%
- EBITDA margin
- -2.69%
- 52-week range
- ₹150 – ₹610
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Kerala Ayurveda Ltd (KERALAYUR) reported revenue of ₹131 crore, net profit of ₹-16 crore and earnings per share of ₹-12.74. That compares with revenue of ₹126 crore and net profit of ₹-14 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹34.74 crore and net profit ₹-7.39 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 80 | 93 | 108 | 126 | 131 |
| Net profit (₹ cr) | 2 | 0 | -1 | -14 | -16 |
| EPS (₹) | 2.24 | -0.85 | -0.47 | -11.6 | -12.74 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 8.40% | 6.25% | 9.21% | 16.02% |
| Stock price CAGR | 9% | 19% | 15% | -71% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 35.61% of Kerala Ayurveda Ltd (KERALAYUR) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.17% and domestic institutional investors (DII) hold 0.04%. Promoters have pledged 20.4% of their holding. Market capitalisation was ₹215 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HUF 4.41%, PORINJU VELIYATH 3.41%, SANJIV DHIRESHBHAI SHAH 2.51%, SANTOSH INDUSTRIES LIMITED 1.85%, SURESH BHATIA HUF 1.77%, DHEERAJ KUMAR LOHIA 1.6%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 35.61% | 20.4% | 0.17% | 0.04% | 64.39% |
| Mar 2026 | 35.61% | 20.4% | 0.17% | 0.04% | 64.39% |
| Dec 2025 | 33.14% | 23.6% | 0.22% | 0.04% | 66.86% |
| Sep 2025 | 33.14% | 23.6% | - | 0.04% | 66.86% |
| Jun 2025 | 37.83% | 20.7% | - | 0.04% | 62.17% |
| Mar 2025 | 58.58% | 13.4% | - | 0.04% | 41.42% |
| Dec 2024 | 58.58% | 13.4% | - | 0.04% | 41.42% |
| Sep 2024 | 58.58% | 13.4% | - | 0.04% | 41.42% |